FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 26, 2023 /PRNewswire/ — Metastatic breast cancer is the advanced stage of breast cancer, including cases wherein cancer has spread to the other parts of the body from the breast. It is also known as stage IV breast cancer. Some of the most common organs which are affected … Read more
– Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care – SAN FRANCISCO, May 26, 2023 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting … Read more
LUND, Sweden, May 26, 2023 /PRNewswire/ — On 26th May 2023, an Annual General Meeting (AGM) was held in Immunovia AB (publ), 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund. Below is a summary of the resolutions made at the AGM. Allocation of the company’s available profits and discharge from liability The AGM resolved … Read more
A roundup of the week’s most newsworthy health industry press releases from PR Newswire, including a Lupus awareness campaign for Black and Hispanic women. NEW YORK, May 26, 2023 /PRNewswire/ — With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering … Read more
GOTHENBURG, Sweden, May 26, 2023 /PRNewswire/ — Tridentify, an international provider of cold-chain monitoring solutions, has announced the launch of its latest innovation – a real-time cold chain monitoring system that includes a ground-breaking feature for continuously monitoring the stability and remaining shelf-life of shipped products in the cold-chain. The new system will transform the way … Read more
ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with ESR1-mutations (ESR1-mut) that are found in up to 40% of tumors In patients whose tumors harbor ESR1-mut, a previous post-hoc subgroup analysis demonstrated that for those with prior … Read more
Exact Sciences’ approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program analysis shows continued, long-term confidence in prognostic value of the Oncotype DX Breast Recurrence Score® 3 New modeling data show superior health outcomes in colorectal cancer screening with Cologuard® compared … Read more
DUBLIN, May 26, 2023 /PRNewswire/ — The “UK Personal Injury Consumer Research Report” report has been added to ResearchAndMarkets.com’s offering. The Personal Injury Consumer Research Report 2023 provides an analysis of results from a survey of 600 individuals going through the claims process in the last 18 months. Where possible in the report, the latest survey … Read more
DUBLIN, May 26, 2023 /PRNewswire/ — The “30-Country IVD Market Atlas (US, China, Germany, UK, Saudi Arabia, India, UAE, France, Vietnam, Turkey and 20 Other Countries)” report has been added to ResearchAndMarkets.com’s offering. Over two decades of publishing in vitro diagnostic market research, the analyst has heard from customers: IVD is a global industry, growth is … Read more
ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with ESR1-mutations (ESR1-mut) that are found in up to 40% of tumors In patients whose tumors harbor ESR1-mut, a previous post-hoc subgroup analysis demonstrated that for those with prior … Read more